Cell therapy TRX103 for active non-infectious uveitis
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a new cell therapy called TRX103 for people with active uveitis not caused by an infection. It aims to see if the treatment is safe and helps reduce eye inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old
- You weigh at least 40 kg (about 88 pounds)
- You have active uveitis that is not caused by an infection (intermediate, posterior, or panuveitis)
- You are on 20 mg or less of prednisone (or a similar steroid) daily, stable for at least 7 days before treatment
- You are not currently taking other strong immune-suppressing drugs like biologics or JAK inhibitors (unless you have stopped them for a required washout period)
- You do not have certain other eye diseases, serious heart, kidney, or liver problems, active infections, or other major health conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
This study follows adults with non-infectious uveitis (intermediate, posterior, or pan-uveitis) to better understand inflammation activity and treatment needs. It also follows adults having planned eye surgery (like cataract or vitreoretinal surgery) to compare groups.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This trial tests a new drug called FXS5626 to treat non-infectious uveitis—inflammation inside the eye that doesn't come from infection. The study looks at whether this drug can reduce eye inflammation and improve vision in people whose condition isn't controlled with steroid eye drops and oral steroids alone.
This Phase 3 study tests whether IRX-101 is safe and well-tolerated in people receiving anti-VEGF injections directly into the eye. It may help doctors find a safer way to pair this study treatment with standard eye injection care.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
Hear when a new Non Infectious Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.